Pancreatic Cancer Research

ResearcherMedical University of LodzActive in the last 2 years

Piotr Hogendorf

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4458-0145; OpenAlex author ID A5045090103. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 16

  1. Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges. Last author DOI 10.1007/s11239-026-03253-z↗
  2. Perioperative Thyroid-Metabolic Changes in Pancreatic Ductal Adenocarcinoma According to Surgical Management. Co-author DOI 10.3390/cancers18111769↗
  3. The effect of gastrojejunostomy on carbohydrate metabolism in patients with pancreatic cancer. Co-author DOI 10.5114/pg.2026.160484↗
  4. Peripheral Eosinophil Count May Be the Prognostic Factor for Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Treatment. Co-author DOI 10.3390/biomedicines12112596↗
  5. Increased GPR35 expression in human colorectal and pancreatic cancer samples: A preliminary clinical validation of a new biomarker. Co-author DOI 10.17219/acem/157291↗
  6. FT3 to FT4 Conversion Ratio May Be an Independent Prognostic Factor in Pancreatic Cancer Patients. Co-author DOI 10.3390/biomedicines11010077↗
  7. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature. Last author DOI 10.1080/1354750x.2021.1876770↗
  8. The Role of microRNA in Pancreatic Cancer. Last author DOI 10.3390/biomedicines9101322↗
  9. Thyroid hormones concentration in portal and peripheral blood in patients with pancreatic cancer: Preliminary study. First author DOI 10.3233/cbm-201595↗
  10. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series. Co-author DOI 10.5604/01.3001.0014.0950↗
  11. Metastatic Pancreatic Cancer. Co-author DOI 10.1080/08941939.2017.1291774↗
  12. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis. Co-author DOI 10.1097/mpa.0000000000000696↗
  13. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Co-author DOI 10.1155/2017/3276806↗
  14. The concentration of D-dimers in portal blood positively correlates with overall survival in patients with non-resectable pancreatic cancer. Co-author DOI 10.1186/s12957-017-1291-4↗
  15. D-dimers revisited: a new marker of pancreatic cancer. Co-author DOI 10.1097/coc.0000000000000060↗
  16. Very high concentration of D-dimers in portal blood in patients with pancreatic cancer. Co-author DOI 10.2478/v10035-012-0087-z↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Durczyński · 15 shared papers, 2012–2026 · strength 2.54
  2. Janusz Strzelczyk · 13 shared papers, 2012–2026 · strength 1.93
  3. Alicja Majos · 5 shared papers, 2020–2026 · strength 1.17
  4. Oliwia Grząsiak · 4 shared papers, 2022–2026 · strength 1.03
  5. Wojciech Ciesielski · 3 shared papers, 2022–2026 · strength 0.71
  6. Aleksander Skulimowski · 5 shared papers, 2017–2021 · strength 0.57
  7. Agata Grochowska · 1 shared paper, 2026 · strength 0.33
  8. Janusz Strzelczyk · 1 shared paper, 2026 · strength 0.30
  9. Tomasz Mackiewicz · 1 shared paper, 2023 · strength 0.19
  10. Jakub Fichna · 1 shared paper, 2023 · strength 0.19
  11. Beata Smolarz · 1 shared paper, 2021 · strength 0.19
  12. Łukasz Durko · 1 shared paper, 2017 · strength 0.07
  13. Ewa I. Malecka-Panas · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.